Edition:
United Kingdom

Apricus Biosciences Inc (APRI.OQ)

APRI.OQ on NASDAQ Stock Exchange Capital Market

0.27USD
4:13pm BST
Change (% chg)

$-0.01 (-2.64%)
Prev Close
$0.28
Open
$0.28
Day's High
$0.28
Day's Low
$0.27
Volume
128,996
Avg. Vol
182,745
52-wk High
$3.34
52-wk Low
$0.26

Latest Key Developments (Source: Significant Developments)

Apricus Biosciences Says Co Received A Nasdaq Staff Deficiency Letter
Monday, 16 Apr 2018 

April 16 (Reuters) - Apricus Biosciences Inc ::APRICUS BIOSCIENCES SAYS ON APRIL 10, CO RECEIVED A NASDAQ STAFF DEFICIENCY LETTER - SEC FILING.  Full Article

Sabby Management LLC Reports 7.68 Pct Passive Stake In Apricus Biosciences
Thursday, 29 Mar 2018 

March 29 (Reuters) - Apricus Biosciences Inc ::SABBY MANAGEMENT LLC REPORTS 7.68 PERCENT PASSIVE STAKE IN APRICUS BIOSCIENCES INC AS OF MARCH 28 - SEC FILING.  Full Article

Apricus Biosciences Announces Scheduling Of Vitaros End-Of-Review Meeting With FDA
Monday, 26 Mar 2018 

March 26 (Reuters) - Apricus Biosciences Inc ::APRICUS BIOSCIENCES ANNOUNCES SCHEDULING OF VITAROS™ END-OF-REVIEW MEETING WITH FDA.APRICUS BIOSCIENCES INC - END-OF-REVIEW MEETING WITH U.S. FDA NOW SCHEDULED TO BE HELD ON APRIL 12.APRICUS BIOSCIENCES INC - INTEND TO FURTHER CLARIFY DEFICIENCIES RAISED IN CRL AND INFORMATION THAT MAY BE NEEDED TO RESOLVE SUCH DEFICIENCIE.  Full Article

Apricus Biosciences files for mixed shelf of up to $100 million
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Apricus Biosciences Inc :Apricus Biosciences files for mixed shelf of up to $100 million - SEC filing.  Full Article

Apricus Biosciences reports Q3 loss per share $0.29
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Apricus Biosciences Inc :Apricus Biosciences Inc provides corporate update and third quarter 2017 financial results.Q3 loss per share $0.29.Apricus Biosciences Inc - ‍as of September 30, 2017, company's cash totaled $8.5 million, compared to $2.1 million as of December 31, 2016​.  Full Article

Apricus Biosciences and certain investors mutually agreed to terminate certain securities purchase agreement
Wednesday, 28 Sep 2016 

Apricus Biosciences Inc : On Sept 27, co and certain investors mutually agreed to terminate certain securities purchase agreement, dated Sept 22 . Entered into a new securities purchase agreement for sale by co of 13.1 million shares of co's common stock, par value $0.001per share .Net proceeds are expected to be approximately $4.2 million and will be used for general corporate and working capital purposes.  Full Article

Apricus Biosciences to issue about 13.1 mln shares at $0.35 per share
Friday, 23 Sep 2016 

Apricus Biosciences Inc [APRI.O] : Apricus Biosciences announces $4.6 million registered direct offering .In connection with offering, will issue about 13.1 million registered shares of common stock at a purchase price of $0.35 per share.  Full Article

Apricus Biosciences says gets $4.5 mln in upfront payments from Ferring
Monday, 15 Aug 2016 

Apricus Biosciences Inc : Company's partner in United Kingdom, has received United Kingdom marketing authorization for Vitaros .Under terms of agreement, Apricus has received a total of $4.5 million in upfront payments from Ferring.  Full Article

Apricus Biosciences announces completion of transfer of Vitaros German marketing authorization to Ferring Pharmaceuticals
Wednesday, 10 Aug 2016 

Apricus Biosciences Inc :Ferring Pharmaceuticals, company's new partner in Germany, has received German marketing authorization for Vitaros.  Full Article

Apricus Biosciences Q2 shr loss $0.05
Thursday, 4 Aug 2016 

Apricus Biosciences Inc : Q2 loss per share $0.05 . Q2 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S .Apricus biosciences provides corporate update and second quarter financial results.  Full Article

BRIEF-Apricus Biosciences Says Co Received A Nasdaq Staff Deficiency Letter

* APRICUS BIOSCIENCES SAYS ON APRIL 10, CO RECEIVED A NASDAQ STAFF DEFICIENCY LETTER - SEC FILING Source : https://bit.ly/2JMowAJ Further company coverage: (Reuters.Briefs@thomsonreuters.com)